Economic Evaluations of Gastroesophageal Reflux Disease Medical Management.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 8, p. 745, doi. 10.1007/s40273-014-0164-8
- By:
- Publication type:
- Article
Works matching IS 11707690 AND DT 2014 AND VI 32 AND IP 8
Results: 8
1
2
Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 8, p. 775, doi. 10.1007/s40273-014-0165-7
- By:
- Publication type:
- Article
3
Do Changes in Drug Coverage Policy Point to an Increased Role for Cost-Effectiveness Analysis in the USA?
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 8, p. 729, doi. 10.1007/s40273-014-0166-6
- By:
- Publication type:
- Article
4
A Review of the Psychometric Properties of Generic Utility Measures in Multiple Sclerosis.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 8, p. 759, doi. 10.1007/s40273-014-0167-5
- By:
- Publication type:
- Article
5
The Better than Dead Method: Feasibility and Interpretation of a Valuation Study.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 8, p. 789, doi. 10.1007/s40273-014-0168-4
- By:
- Publication type:
- Article
6
A Cost-effectiveness Study of Intravenous Immunoglobulin in Childhood Idiopathic Thrombocytopenia Purpura Patients with Life-Threatening Bleeding.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 8, p. 801, doi. 10.1007/s40273-014-0171-9
- By:
- Publication type:
- Article
7
Transparency in Reimbursement Decisions: In Whose Best Interest?
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 8, p. 725, doi. 10.1007/s40273-014-0176-4
- By:
- Publication type:
- Article
8
Modelling the Cost Effectiveness of Interventions for Osteoporosis: Issues to Consider.
- Published in:
- PharmacoEconomics, 2014, v. 32, n. 8, p. 735, doi. 10.1007/s40273-014-0156-8
- By:
- Publication type:
- Article